Pfizer (Pfizer) Valuation Rank

View and export this data going back to 1951. Start your Free Trial

What is Pfizer Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pfizer Valuation Rank Related Terms

Thank you for viewing the detailed overview of Pfizer's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (Pfizer) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFEB:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Executives

Scott Gottlieb	director	MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff	officer: Executive Vice President	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico	officer: SVP & Controller	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni	officer: Executive Vice President	ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr	officer: Executive Vice President	600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler	officer: Senior Vice President	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten	officer: Senior Vice President	5 GIRALDA FARMS, MADISON NJ 07940
David M Denton	officer: Chief Financial Officer & EVP	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao	officer: Executive Vice President	C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott	officer: Executive Vice President	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson	officer: Executive Vice President	PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie	officer: Executive Vice President	C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman	officer: Senior Vice President	767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang	officer: Group President	235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young	officer: Business Unit President	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017